RSV vaccines

A study evaluating RSV intervention cost effectiveness in 133 LMICs found that RSV interventions could be cost saving in one-third of countries evaluated and cost-effective in the remaining countries at willingness-to-pay threshold of 0.5 GDP per capita and when the price for the maternal vaccines was $3.50 and the price of the mAb was $3.50. ^{Go to footnote 11}

Given lower anticipated prices for maternal RSVpreF, immunization is expected to be more cost-effective than using nirsevimab. ^{Go to footnote 22}